Brokerages Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Price Target at $7.67

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $7.6667.

A number of analysts have commented on NMRA shares. Guggenheim reaffirmed a “buy” rating and set a $14.00 target price on shares of Neumora Therapeutics in a report on Tuesday, March 31st. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Neumora Therapeutics in a research report on Tuesday, March 31st. William Blair upgraded shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Tuesday, April 21st.

Neumora Therapeutics Stock Down 48.6%

Shares of NMRA stock opened at $0.91 on Thursday. Neumora Therapeutics has a 12 month low of $0.72 and a 12 month high of $3.65. The stock has a market cap of $169.44 million, a P/E ratio of -0.69 and a beta of 2.74. The company has a current ratio of 5.09, a quick ratio of 5.09 and a debt-to-equity ratio of 0.75. The company has a 50 day simple moving average of $1.95 and a two-hundred day simple moving average of $2.24.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Thursday, May 7th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. On average, research analysts expect that Neumora Therapeutics will post -0.95 earnings per share for the current year.

Hedge Funds Weigh In On Neumora Therapeutics

A number of hedge funds have recently modified their holdings of the company. Legacy Private Trust Co. boosted its position in shares of Neumora Therapeutics by 35.7% in the fourth quarter. Legacy Private Trust Co. now owns 19,000 shares of the company’s stock worth $34,000 after purchasing an additional 5,000 shares during the period. Invesco Ltd. boosted its position in shares of Neumora Therapeutics by 6.8% in the second quarter. Invesco Ltd. now owns 132,038 shares of the company’s stock worth $97,000 after purchasing an additional 8,383 shares during the period. Hsbc Holdings PLC bought a new position in shares of Neumora Therapeutics in the fourth quarter worth approximately $27,000. Virtu Financial LLC bought a new position in shares of Neumora Therapeutics in the third quarter worth approximately $31,000. Finally, Barclays PLC boosted its position in shares of Neumora Therapeutics by 202.0% in the fourth quarter. Barclays PLC now owns 30,924 shares of the company’s stock worth $55,000 after purchasing an additional 20,683 shares during the period. 47.65% of the stock is currently owned by institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.